Bovalto Ibraxion

RSS

Withdrawn

This medicine's authorisation has been withdrawn

infectious bovine rhinotracheitis vaccine (inactivated)
MedicineVeterinaryWithdrawn

Czech is available via eTranslation, the European Commission's machine translation service.

Translate to Czech | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The marketing authorisation for Bovalto Ibraxion has been withdrawn at the request of the marketing authorisation holder.

български (BG) (273.86 KB - PDF)

Zobrazit

español (ES) (211.53 KB - PDF)

Zobrazit

čeština (CS) (261.66 KB - PDF)

Zobrazit

dansk (DA) (213.32 KB - PDF)

Zobrazit

Deutsch (DE) (220.08 KB - PDF)

Zobrazit

eesti (ET) (204.87 KB - PDF)

Zobrazit

ελληνικά (EL) (286.33 KB - PDF)

Zobrazit

français (FR) (212.65 KB - PDF)

Zobrazit

hrvatski (HR) (231.45 KB - PDF)

Zobrazit

italiano (IT) (209.38 KB - PDF)

Zobrazit

latviešu (LV) (244.51 KB - PDF)

Zobrazit

lietuvių (LT) (233 KB - PDF)

Zobrazit

magyar (HU) (249.94 KB - PDF)

Zobrazit

Malti (MT) (258.21 KB - PDF)

Zobrazit

Nederlands (NL) (211.02 KB - PDF)

Zobrazit

polski (PL) (256.51 KB - PDF)

Zobrazit

português (PT) (211.11 KB - PDF)

Zobrazit

română (RO) (235.21 KB - PDF)

Zobrazit

slovenčina (SK) (258.12 KB - PDF)

Zobrazit

slovenščina (SL) (244.33 KB - PDF)

Zobrazit

suomi (FI) (209.31 KB - PDF)

Zobrazit

svenska (SV) (209.74 KB - PDF)

Zobrazit

Product information

български (BG) (705.71 KB - PDF)

Zobrazit

español (ES) (674.36 KB - PDF)

Zobrazit

čeština (CS) (969.79 KB - PDF)

Zobrazit

dansk (DA) (624.29 KB - PDF)

Zobrazit

Deutsch (DE) (661.81 KB - PDF)

Zobrazit

eesti (ET) (692.55 KB - PDF)

Zobrazit

ελληνικά (EL) (1.19 MB - PDF)

Zobrazit

français (FR) (671.79 KB - PDF)

Zobrazit

hrvatski (HR) (767.57 KB - PDF)

Zobrazit

italiano (IT) (679.81 KB - PDF)

Zobrazit

latviešu (LV) (999.57 KB - PDF)

Zobrazit

lietuvių (LT) (791.74 KB - PDF)

Zobrazit

magyar (HU) (981.94 KB - PDF)

Zobrazit

Malti (MT) (1007.77 KB - PDF)

Zobrazit

Nederlands (NL) (671.31 KB - PDF)

Zobrazit

polski (PL) (993.05 KB - PDF)

Zobrazit

português (PT) (664.06 KB - PDF)

Zobrazit

română (RO) (792.26 KB - PDF)

Zobrazit

slovenčina (SK) (995.67 KB - PDF)

Zobrazit

slovenščina (SL) (960.57 KB - PDF)

Zobrazit

suomi (FI) (678.92 KB - PDF)

Zobrazit

svenska (SV) (676.34 KB - PDF)

Zobrazit

Íslenska (IS) (680.52 KB - PDF)

Zobrazit

norsk (NO) (684.14 KB - PDF)

Zobrazit
Latest procedure affecting product information:IAIN/0016
10/08/2016

български (BG) (333.69 KB - PDF)

Zobrazit

español (ES) (172.7 KB - PDF)

Zobrazit

čeština (CS) (205.62 KB - PDF)

Zobrazit

dansk (DA) (172.68 KB - PDF)

Zobrazit

Deutsch (DE) (173.21 KB - PDF)

Zobrazit

eesti (ET) (168.31 KB - PDF)

Zobrazit

ελληνικά (EL) (215.76 KB - PDF)

Zobrazit

français (FR) (171.23 KB - PDF)

Zobrazit

hrvatski (HR) (192.67 KB - PDF)

Zobrazit

italiano (IT) (168.65 KB - PDF)

Zobrazit

latviešu (LV) (209.34 KB - PDF)

Zobrazit

lietuvių (LT) (200.78 KB - PDF)

Zobrazit

magyar (HU) (191.94 KB - PDF)

Zobrazit

Malti (MT) (214.75 KB - PDF)

Zobrazit

Nederlands (NL) (170.59 KB - PDF)

Zobrazit

polski (PL) (207.14 KB - PDF)

Zobrazit

português (PT) (172.47 KB - PDF)

Zobrazit

română (RO) (195.44 KB - PDF)

Zobrazit

slovenčina (SK) (209.19 KB - PDF)

Zobrazit

slovenščina (SL) (240.02 KB - PDF)

Zobrazit

suomi (FI) (166.83 KB - PDF)

Zobrazit

svenska (SV) (172.67 KB - PDF)

Zobrazit

Íslenska (IS) (170.24 KB - PDF)

Zobrazit

norsk (NO) (168.61 KB - PDF)

Zobrazit

Product details

Name of medicine
Bovalto Ibraxion
Active substance
inactivated IBR virus
International non-proprietary name (INN) or common name
infectious bovine rhinotracheitis vaccine (inactivated)
Species
Cattle
Anatomical therapeutic chemical veterinary (ATCvet) code
QI02AA03

Pharmacotherapeutic group

Immunologicals for Bovidae

Therapeutic indication

Active immunisation of cattle to reduce the clinical signs of infectious bovine rhinotracheitis (IBR) and field virus excretion.
The onset of immunity is 14 days and the duration of immunity is 6 months.

Authorisation details

EMA product number
EMEA/V/C/000051
Marketing authorisation holder
Merial

29 Avenue Tony Garnier
69007 Lyon
France

Marketing authorisation issued
09/03/2000
Revision
10

Assessment history

This page was last updated on

Share this page